Overview

Cell MedX Corp. is a research and development company publicly traded on the OTC Markets under the symbol CMXC. The Company is focused on the discovery, design, development, manufacture and commercialization of clinical therapeutic and wellness products for individuals who want more control over managing their health and general wellness.

Cell MedX is committed to individuals managing their well-being through the use of microcurrent therapeutic technology. The eBalance® is a compact, safe and easy-to-use microcurrent device. Cell MedX is committed to advancing research in the use of eBalance® technology through therapeutic device development, safety testing and observational clinical studies. The observational clinical studies were administered by a third party and authorized by Health Canada.

The studies were completed in 2017, with the completed eBalance® Clinical Report received in January 2018. These findings show encouraging results which confirm safety and areas of individual-reported therapeutic benefit that warrant further investigation. Once Cell MedX has received a Class II Medical Device designation in both Canada & the USA, Cell MedX plans to begin additional R&D observational clinical studies including the eBalance® Experience Study which conforms to the standards of the Canadian Tri-Council Research Ethics Guidelines